News
Two recent studies published this week assess the low uptake of respiratory syncytial virus (RSV) vaccine among US veterans ...
The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...
Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...
Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore ...
French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...
Vermont has the second lowest state fatality rate in the US (148.4 per 100K; Hawaii 113.7/100K). Mississippi (466/100K) and ...
Vicebio Ltd, a biopharmaceutical company developing novel vaccines, has entered an exclusive, definitive agreement to be ...
The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...
Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...
Sanofi has announced that it will be expanding its respiratory vaccines pipeline by acquiring UK-based Vicebio for up to ...
Vicebio, a biopharmaceutical company that develops vaccines for serious respiratory viral infections, has agreed to be ...
French pharma major Sanofi today announced it has entered into an agreement to acquire Vicebio, a privately held biotechnology company headquartered in London, UK.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results